Your skin,

our care

Skin treatment

Clinical studies around the world have shown that Philips Phototherapy lamps are the most effective lamps currently available for the treatment of Psoriasis, Vitiligo and other skin diseases.
A video about UV-Phototherapy : an effective and proven treatment method for skin diseases

Effective treatment of 
Psoriasis

 

30 - 50% of psoriasis is thought to be hereditary disease. It cannot be transmitted from person to person. It often first appears in adolescence, but is not uncommon in children and middle-aged adults.

Diagnosis of Psoriasis

 

Psoriasis is usually diagnosed just by looking at the affected areas of the body, although some clinics also take skin samples to rule out any other diagnosis.

 

It is important to talk to your doctor about any form of psoriasis for referral to an appropriate specialist.

A woman touching her back with her hands

Treatment possibilities for Psoriasis

 

Dermatologists may recommend topical treatments, including lotions and moisturisers. Treatments based on Salicylic Acid help to remove scales and are often used in conjunction with other treatments. Topical steroids can also be prescribed and they work very well on more moderate cases of psoriasis. Treatments based on vitamin D are also very useful in fighting Psoriasis.

 

Another alternative is Phototherapy, which involves subjecting the skin to waves of ultraviolet light. There are three types of ultraviolet light, UVA, UVB and UVC. There are treatments available using UVB light, lasers or UVA light combined with a medication called Psoralen (PUVA).

 

Some people report that minimizing stress and consuming a healthy diet, combined with rest, sunshine and swimming in saltwater can help. This type of lifestyle treatment is suggested as a long-term management strategy, rather than an initial treatment of severe Psoriasis.

 

The following links may provide further helpful sources of information.

 

National Psoriasis Foundation

UK Psoriasis Help Forum

SkinCell

 

Effective treatment of
Vitiligo

 

Unlike Psoriasis, the possibilities for treating vitiligo are limited to phototherapy, except for a small number of patients with stable vitiligo, who can be treated with skin autologous pigment grafts.
 

The first report of the use of ""phototherapy"" in the treatment of skin disorders dates from about 1400 BC among Hindus, as already mentioned. They used ""photochemotherapy""-administration of plant extracts, followed by sun exposure-for vitiligo. The same treatment was also used in ancient Egypt. The active ingredients in these plant extracts were isolated in 1947 by Fahmy et al. as 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen (MOP). In the same year, these authors and also El Mofty started to treat patients with vitiligo with 8-MOP and sun exposure.
 

Kromayer, a German dermatologist, designed in 1904 a water cooled mercury vapor UV lamp. He was the first to treat vitiligo with artificial UVB.
 

In 1969 Fulton et al. used "black light" UVA tubes for the first time in combination with topical 8-MOP in the treatment of vitiligo. Parrish and Fitzpatrick introduced modern photochemotherapy with 8-MOP, having a peak sensitivity at 330 nm and UVA fluorescent tubes. They used fluorescent tubes emitting in the 320 - 380 nm waveband in the PUVA treatment of vitiligo. Although late effects, e.g. skin carcinogenesis, have rarely been reported in vitiligo, the frequently observed phototoxic responses were considered a severe practical problem.

Unlike Psoriasis, the possibilities for treating vitiligo are limited to phototherapy, except for a small number of patients with stable vitiligo, who can be treated with skin autologous pigment grafts.

The first report of the use of ""phototherapy"" in the treatment of skin disorders dates from about 1400 BC among Hindus, as already mentioned. They used ""photochemotherapy""-administration of plant extracts, followed by sun exposure-for vitiligo. The same treatment was also used in ancient Egypt. The active ingredients in these plant extracts were isolated in 1947 by Fahmy et al. as 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen (MOP). In the same year, these authors and also El Mofty started to treat patients with vitiligo with 8-MOP and sun exposure.

Kromayer, a German dermatologist, designed in 1904 a water cooled mercury vapor UV lamp. He was the first to treat vitiligo with artificial UVB.

In 1969 Fulton et al. used "black light" UVA tubes for the first time in combination with topical 8-MOP in the treatment of vitiligo. Parrish and Fitzpatrick introduced modern photochemotherapy with 8-MOP, having a peak sensitivity at 330 nm and UVA fluorescent tubes. They used fluorescent tubes emitting in the 320 - 380 nm waveband in the PUVA treatment of vitiligo. Although late effects, e.g. skin carcinogenesis, have rarely been reported in vitiligo, the frequently observed phototoxic responses were considered a severe practical problem.

Unlike Psoriasis, the possibilities for treating vitiligo are limited to phototherapy, except for a small number of patients with stable vitiligo, who can be treated with skin autologous pigment grafts.

The first report of the use of ""phototherapy"" in the treatment of skin disorders dates from about 1400 BC among Hindus, as already mentioned. They used ""photochemotherapy""-administration of plant extracts, followed by sun exposure-for vitiligo. The same treatment was also used in ancient Egypt. The active ingredients in these plant extracts were isolated in 1947 by Fahmy et al. as 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen (MOP). In the same year, these authors and also El Mofty started to treat patients with vitiligo with 8-MOP and sun exposure.

Kromayer, a German dermatologist, designed in 1904 a water cooled mercury vapor UV lamp. He was the first to treat vitiligo with artificial UVB.

In 1969 Fulton et al. used "black light" UVA tubes for the first time in combination with topical 8-MOP in the treatment of vitiligo. Parrish and Fitzpatrick introduced modern photochemotherapy with 8-MOP, having a peak sensitivity at 330 nm and UVA fluorescent tubes. They used fluorescent tubes emitting in the 320 - 380 nm waveband in the PUVA treatment of vitiligo. Although late effects, e.g. skin carcinogenesis, have rarely been reported in vitiligo, the frequently observed phototoxic responses were considered a severe practical problem.

Unlike Psoriasis, the possibilities for treating vitiligo are limited to phototherapy, except for a small number of patients with stable vitiligo, who can be treated with skin autologous pigment grafts.

The first report of the use of ""phototherapy"" in the treatment of skin disorders dates from about 1400 BC among Hindus, as already mentioned. They used ""photochemotherapy""-administration of plant extracts, followed by sun exposure-for vitiligo. The same treatment was also used in ancient Egypt. The active ingredients in these plant extracts were isolated in 1947 by Fahmy et al. as 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen (MOP). In the same year, these authors and also El Mofty started to treat patients with vitiligo with 8-MOP and sun exposure.

Kromayer, a German dermatologist, designed in 1904 a water cooled mercury vapor UV lamp. He was the first to treat vitiligo with artificial UVB.

In 1969 Fulton et al. used "black light" UVA tubes for the first time in combination with topical 8-MOP in the treatment of vitiligo. Parrish and Fitzpatrick introduced modern photochemotherapy with 8-MOP, having a peak sensitivity at 330 nm and UVA fluorescent tubes. They used fluorescent tubes emitting in the 320 - 380 nm waveband in the PUVA treatment of vitiligo. Although late effects, e.g. skin carcinogenesis, have rarely been reported in vitiligo, the frequently observed phototoxic responses were considered a severe practical problem.

Unlike Psoriasis, the possibilities for treating vitiligo are limited to phototherapy, except for a small number of patients with stable vitiligo, who can be treated with skin autologous pigment grafts.

The first report of the use of ""phototherapy"" in the treatment of skin disorders dates from about 1400 BC among Hindus, as already mentioned. They used ""photochemotherapy""-administration of plant extracts, followed by sun exposure-for vitiligo. The same treatment was also used in ancient Egypt. The active ingredients in these plant extracts were isolated in 1947 by Fahmy et al. as 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen (MOP). In the same year, these authors and also El Mofty started to treat patients with vitiligo with 8-MOP and sun exposure.

Kromayer, a German dermatologist, designed in 1904 a water cooled mercury vapor UV lamp. He was the first to treat vitiligo with artificial UVB.

In 1969 Fulton et al. used "black light" UVA tubes for the first time in combination with topical 8-MOP in the treatment of vitiligo. Parrish and Fitzpatrick introduced modern photochemotherapy with 8-MOP, having a peak sensitivity at 330 nm and UVA fluorescent tubes. They used fluorescent tubes emitting in the 320 - 380 nm waveband in the PUVA treatment of vitiligo. Although late effects, e.g. skin carcinogenesis, have rarely been reported in vitiligo, the frequently observed phototoxic responses were considered a severe practical problem.

UVB Narrowband (/01) therapy

 

Narrowband (NB)-UVB, or nm UVB (Philips TL 01) has been used in the treatment of vitiligo now for 10 years and was first reported by Westerhof and Nieuweboer-Krobotova. It is now considered as the treatment of choice, because of its advantages over PUVA treatment being: UVB 311 nm is more effective than PUVA and safer, as there are no psoralen-induced side effects and can be used in children and pregnant woman. The NB-UVB can also be achieved with the eximer laser (308 nm). A draw back is that only small areas can be treated at one time and the eximer laser is excluded from home treatment. Narrowband UVB is also recommended in combination with pigmentcel grafting of vitiligo lesions.

Close look to a woman’s eyes

Effective treatment of  
Hyperbilirubin

Approximately 10% of new born babies is affected with Hyperbilirubin. An effective way to treat Neonatal Jaundice is with blue light therapy. An example of phototherapy in the visible region is the treatment of hyperbilirubinemia with blue light (400-500 nm). Unconjugated bilirubin, being a decomposition product of haemoglobin, is not fully soluble in water and plasma. In normal physiological circumstances, this unconjugated bilirubin is bound to albumin and transported to the liver where it is converted by glucuronyltransferase into the water-soluble conjugated form and excreted in the bile. When the albumin binding capacity of the plasma is exceeded (e.g. in icterus neonatorum, in Crigler Najjar syndrome, etc), the unconjugated bilirubin can diffuse into the tissues. Blue light can convert this unconjugated form into a more watersoluble form by a photo-oxidative process and an isomerization process.
A baby’s foots
The graph illustrates the spectrum of a blue lamp TL/52, just emitting at the maximum effective wavelength of 450 nm. The blue light component in halogen dichroic mirror lamps can also be used (UV and IR filtering is necessary). There has also been research showing the bilirubin content of the plasma being lowered with the help of green light (‘TL’/50). However, the results are still not convincing enough to warrant a change from blue light. The effective use of phototherapy has eliminated the need for exchange transfusion in almost all jaundiced infants. Care must be taken to ensure effective irradiance delivery, to maximize skin exposure and to provide eye protection.
In 1969 Fulton et al. used "black light" UVA tubes for the first time in combination with topical 8-MOP in the treatment of vitiligo. Parrish and Fitzpatrick introduced modern photochemotherapy with 8-MOP, having a peak sensitivity at 330 nm and UVA fluorescent tubes. They used fluorescent tubes emitting in the 320 - 380 nm waveband in the PUVA treatment of vitiligo. Although late effects, e.g. skin carcinogenesis, have rarely been reported in vitiligo, the frequently observed phototoxic responses were considered a severe practical problem.
A graph illustrates the spectrum of a blue lamp TL/52

Effective treatment of  
Atopic Dermatitis

 

The therapy of Atopic Dermatitis includes mainly corticosteroids (CS), antihistamines and immunosuppressors. CS are known to cause a variety of side effects and attempts have been made to reduce or eliminate their use through alternative methods such as phototherapy (UVA/UVB, UVA(1), UVA(2), UVB 311 nm). In the majority of patients, UV irradiation proves favorable.

 

The active spectrum is mostly in the UV range, between 300 and 400 nm (equipment with TL/10 (=UVA-2), 'TL'/09, filtered HPA). The dosage (quality and quantity of radiation) has to be adjusted to the individual response of the patient and possibly (in case of a reaction of adaptation) be altered in the course of the therapy.

UV radiation can be used for multiple purposes in water and air treatment, but is primarily employed as a disinfection process that inactivates microorganisms without chemicals. For other applications, UV is used for the removal of organic and inorganic chemicals, including chlorine, chloramines, ozone and Total Organic Carbon (TOC) emerging contaminants.

B311 nm UVB therapies has been found to be ideal for following UVA-1 therapy: UVA-1 is used in the initial phase of treatment to manage acute, severe exacerbations of atopic dermatitis and is replaced by nm UVB therapy, which is an effective (and presumably safe) means of maintenance therapy.

 

Because its presumed safety, it has also been advocated to be used for children.

Woman’s body

Effective treatment of 
other skin diseases

 

Psoriasis, which affects about 2% of Caucasians, and vitiligo, which affects a similar percentage of the dark and light-skinned population, are two examples of skin diseases which can be successfully treated with phototheraphy. But the list of skin diseases which can be treated with photochemotherapy is constantly growing.

Some other dermatoses responsive to photochemotherapy are Parapsoriasis, Cutaneous T-cell Lymphoma (Sézary syndrome), Mycosis Fungoides, Lichen Planus, Pityriasis Lichenoides, Pityriasis Rosea, various types of Eczema, Polymorphous light eruption, Furunculosis, Folliculitis, indolent Ulcers, Prurigo and Pruritis, etc.

 

Most of these diseases have now been treated with Narrowband UVB, although in a varying degree of effectiveness, which seem to be as good as PUVA. It has also been stated that exposure to ultraviolet “light” causes an exacerbation or produces injurious effects in the following conditions: Xeroderma Pigmentosum, Herpes Simplex, Lupus Erythematosus, several types of Eczema, prematurely senile skin, Porphyria, the use of immunosuppressive medications (after kidney transplants) and Aids.

A woman touching her back with her hands

Phototherapy products

 

Most effective lamps for skin treatment.

 

View UVB Narrowband lamps

UVB Narrowband PL-L/PL-S
  • Lääketieteellinen loistelamppu /12
    Lääketieteellinen loistelamppu /12
    Putkenmuotoiset tai kompaktit yksikantaiset pienpaineiset elohopeahöyryloistelamput
 UVA (PUVA) PLS/PLL

UVA (PUVA) lamps

Medical Therapy Jaundice TL/TL-D

Jaundice lamps

How does it work?

Read more

Light can help you

 

Philips UVB Narrowband lamps are the most effective on skin

 

Find out more

A woman touching her back with her hands

Effective phototherapy

 

Phototherapy uses specific wavelengths of the sun's natural spectrum for the treatment of Psoriasis, Vitiligo, Hyperbilirubin and other skin diseases.

 

Find out more

Phototherapy treatment

Need support?

 

We have sales office all around the world. There is always one in your neighbourhood.

 

Contact Philips